Immunotherapy vs. Chemotherapy in Montreal: A Patient’s Guide to Side Effects

As a cancer patient in Montreal, being told you’re a candidate for immunotherapy can feel like a beacon of hope. It represents a shift from the well-known realities of traditional chemotherapy to a new frontier of medicine. You’ve likely heard the high-level summary: chemotherapy is a broad-spectrum attack on fast-dividing cells (both cancerous and healthy), while immunotherapy harnesses your own immune system to fight the cancer. This often leads to the assumption that immunotherapy automatically means a gentler, easier experience. While the side effect profile is certainly different, it is not necessarily ‘milder’—it is simply a new language your body is speaking.

The real challenge, and where patients can feel lost, is in deciphering this new language. The side effects of immunotherapy, known clinically as immune-related adverse events (irAEs), are not just byproducts of treatment; they are signs of the very immune activation we are trying to achieve. A rash isn’t just a rash; it might be a signal of treatment efficacy. Fatigue feels different. And perhaps most unsettling, an initial scan might show your tumour is bigger, a phenomenon that could be terrifying without the right context.

This guide is designed to move beyond the simplistic “chemo vs. immuno” comparison. Written from the perspective of an oncology specialist within the Quebec healthcare system, its purpose is to empower you. We will demystify these counter-intuitive effects, ground them in the specific context of Montreal’s leading cancer centres—from the CHUM to the MUHC and the Jewish General Hospital—and provide a concrete roadmap for navigating this journey. We will explore why your unique biology (biomarkers) is the key, how to interpret what you see and feel, and how to access the specific support systems, from your infirmière pivot to provincial drug coverage, that exist for you here in Quebec.

This article will provide a clear, structured overview of these critical differences, helping you partner more effectively with your healthcare team. The following sections break down everything you need to know to navigate your treatment with confidence.

Targeted Therapy vs Chemotherapy: What Is the Real Difference for Your Body?

To understand immunotherapy, it helps to first contrast it with its predecessors. Traditional chemotherapy is often compared to a snowplow clearing a Montreal street after a blizzard: it’s powerful and clears a wide path, but it’s indiscriminate. It removes the snow (cancer cells) but also takes out mailboxes, scrapes the asphalt, and damages curbs (healthy, fast-growing cells like hair follicles, stomach lining, and blood marrow). This collateral damage is why side effects like nausea, hair loss, and low blood counts are so common and predictable.

Targeted therapies and immunotherapies are fundamentally different. They are more like a specialized team with a map, looking for specific addresses (cancer cells with certain markers) to target. Immunotherapy, specifically, doesn’t attack the cancer directly. Instead, it “removes the brakes” from your immune system’s T-cells, allowing them to recognize and attack the cancer. This precision means many of chemotherapy’s hallmark side effects are avoided; for example, statistics show dramatic differences in visible side effects, with significant hair loss affecting under 5% of immunotherapy patients compared to over 65% with many chemo regimens. However, this unleashing of the immune system can cause it to attack healthy tissues, leading to a completely different set of potential issues.

The timeline and nature of these effects are distinct. The following table provides a general comparison of what a patient might experience in the initial months of treatment.

Biomarkers: Why Not Everyone Is a Candidate for Immunotherapy?

Unlike chemotherapy, which is often administered based on the type and stage of cancer, immunotherapy is a highly personalized medicine. The key that unlocks its potential lies within the unique genetic makeup of your tumour, specifically through something called biomarkers. These are like flags on the surface of cancer cells that tell us whether your immune system can be effectively “unleashed” to fight them. Without the right biomarker, immunotherapy can be ineffective and expose you to side effects without benefit.

The most common biomarker for many cancers is PD-L1 (Programmed Death-Ligand 1). Think of PD-L1 as a “don’t see me” signal that cancer cells use to hide from your immune system. Immunotherapy drugs called “checkpoint inhibitors” block this signal, allowing your T-cells to see and attack the cancer. The higher the expression of PD-L1 in a tumour, the more likely the treatment is to work. In non-small cell lung cancer (NSCLC), for instance, clinical data demonstrates a 45% response rate in patients with high PD-L1 expression, compared to much lower rates in those with little or no expression. Other important biomarkers include MSI-H/dMMR and Tumour Mutation Burden (TMB), which also indicate a high likelihood of response.

Here in Montreal, our major cancer centres like the MUHC, CHUM, and the Jewish General Hospital have streamlined the biomarker testing process. A small sample from your tumour biopsy is analyzed in a pathology lab. Basic PD-L1 testing, which is covered by RAMQ, typically returns results within a week, while more extensive genomic profiling can take a few weeks and may have associated costs. Your oncologist will use these results to determine not just *if* you are a candidate for immunotherapy, but which specific drug is most likely to benefit you. This is the heart of precision oncology.

Detecting Cancer in Blood: How Liquid Biopsies Replace Invasive Surgery?

The need to analyze biomarkers brings up a practical and often daunting question for patients: does this mean another invasive surgical biopsy? Traditionally, obtaining a tissue sample required a procedure, which could be difficult, painful, and sometimes impossible depending on the tumour’s location. However, a revolutionary technology is changing the landscape of cancer diagnostics in Montreal and around the world: the liquid biopsy.

A liquid biopsy is a simple blood test. It works by detecting tiny fragments of DNA and other substances that are shed by tumours into the bloodstream (called circulating tumour DNA or ctDNA). By analyzing this ctDNA, oncologists can identify the same critical biomarkers—like PD-L1 status or specific mutations—that would be found in a traditional tissue biopsy. This is a game-changer for several reasons. It’s minimally invasive, can be repeated easily over time to monitor treatment response or detect resistance, and provides a comprehensive picture of the cancer’s genetic profile from all tumour sites, not just one biopsy location.

Montreal is at the forefront of this technology. The Montreal Cancer Consortium, which includes the Jewish General Hospital’s Segal Cancer Centre, is a hub for liquid biopsy research, leveraging data from thousands of patients to refine its clinical use. The patient experience between the two methods is profoundly different, as outlined below.

While traditional biopsies remain the gold standard for initial diagnosis, liquid biopsies are increasingly used for treatment selection and monitoring. It’s a powerful tool that makes personalized medicine more accessible and less burdensome for patients.

Why Immunotherapy Might Cause ‘Pseudo-Progression’ on Your Scans?

One of the most anxiety-inducing moments for a cancer patient is waiting for the results of their first scan after starting a new treatment. With immunotherapy, this moment can be particularly confusing. In a small but significant number of patients, the first scan may show that the tumours have actually gotten larger, or new, smaller lesions may appear. In the world of chemotherapy, this would be clear evidence of treatment failure. With immunotherapy, it could be the exact opposite: a sign of pseudo-progression.

Pseudo-progression is a phenomenon unique to immunotherapy. It occurs because the treatment works by activating your immune cells (T-cells) to infiltrate the tumour. This influx of a cellular army can cause the tumour to swell and appear larger on a CT or MRI scan, even as the cancer cells within are being destroyed. It’s the “inflammation” of the battlefront, not necessarily the growth of the enemy itself. This is a critical distinction, as stopping treatment based on this initial scan could mean abandoning a therapy that is actually working.

Montreal’s major cancer centres have established clear protocols for this situation. Oncologists at the CHUM, MUHC, and Jewish General Hospital are well-versed in this phenomenon, thanks in part to Montreal’s leading role in immunotherapy trials. If pseudo-progression is suspected, a multidisciplinary tumour board will review your imaging using special criteria (iRECIST) to help differentiate it from true progression. Your infirmière pivot (pivot nurse) is a key resource during this uncertain time, providing education and support. Typically, the treatment is continued, and a follow-up scan is scheduled in 4-8 weeks to confirm the trend. If it was pseudo-progression, the subsequent scan will show the tumours are now shrinking.

The Specific Rash That Indicates Your Immunotherapy Is Working (Or Dangerous)

Of all the immune-related side effects, skin reactions are among the most common and visible. These can range from a mild, itchy rash to more severe, blistering conditions. While any new symptom should be reported, this particular side effect carries a fascinating dual message. On one hand, it’s an adverse event that needs management. On the other hand, it is often a powerful external sign that your immune system has been successfully activated and is ready to fight.

Several studies have drawn a direct line between the development of certain immune-related skin reactions and better treatment outcomes. In fact, some research indicates that 36% of patients experiencing mild skin reactions show a positive immunotherapy response, suggesting these effects are a marker of the desired immune engagement. The challenge for you and your care team is to manage the discomfort without suppressing the immune response too much, and to distinguish a manageable reaction from a dangerous one.

Managing this requires a graded approach, especially in Montreal’s climate. The dry air of a Quebec winter can exacerbate skin dryness and itching, while the intense summer sun can be a problem due to increased photosensitivity. Your oncology day clinic at the CHUM or MUHC will have a clear protocol. Mild rashes (Grade 1) can often be managed with over-the-counter hydrocortisone creams from a local pharmacy like Jean Coutu or Pharmaprix. Moderate rashes (Grade 2) may require prescription steroid creams or a temporary pause in treatment. A severe, blistering, or peeling rash (Grade 3 or higher) is a medical emergency and requires an immediate visit to the ER, as it can be a sign of a life-threatening systemic reaction.

How Long Do You Stay on Immunotherapy If the Cancer Disappears?

Reaching a state of “complete response,” where scans show no evidence of cancer, is the ultimate goal of treatment. With chemotherapy, this milestone typically marks the end of a treatment course. With immunotherapy, the answer is more complex and one of the most debated topics in modern oncology. The very nature of immunotherapy—creating a long-term “memory” in your immune system to keep the cancer at bay—raises a difficult question: when is it safe to stop?

There is no single answer, as the decision is highly personalized. Canadian oncologists generally follow protocols that recommend a standard course of treatment, often lasting for up to two years, even after a complete response has been achieved. The rationale is to consolidate the gains and ensure the immune system’s surveillance is firmly established to prevent a relapse. This is particularly true for cancers like melanoma, where the durability of response is a key objective. The decision to stop involves weighing the ongoing risk of side effects against the potential benefit of continued treatment.

This phase of treatment brings its own unique psychological challenges. After months or years of actively “doing something” to fight the cancer, the idea of stopping can be terrifying. It can feel like taking away the very safety net that has been so effective. As one expert noted, this is a profound dilemma for patients.

The anxiety of stopping a successful treatment versus the relief from chronic side effects represents one of the most challenging psychological aspects for patients achieving complete remission

– Quebec-based psycho-oncologist, Montreal Cancer Consortium Research Report

This is where ongoing, open communication with your oncology team and psycho-oncology support services becomes paramount. Your team will help you navigate this decision, balancing clinical evidence with your personal quality of life, to determine the optimal duration of therapy for your specific situation.

Are New Immunotherapy Drugs Covered by the ‘Patient d’exception’ Measure?

The science of immunotherapy is advancing at a breathtaking pace, with new and more effective drugs becoming available. However, for a patient in Quebec, a crucial question follows any clinical breakthrough: is it covered by RAMQ? There can be a significant lag time between a drug’s approval by Health Canada and its inclusion on the provincial formulary. This is where a critical mechanism called the Mesure du patient d’exception comes into play.

This measure is designed for situations where a patient has exhausted all standard, provincially covered treatment options, but a new, unlisted drug offers a strong chance of clinical benefit. It allows your oncologist to make a special request on your behalf for the government to cover the cost of the drug. The process is rigorous and not guaranteed. Your oncologist, often at a major center like Hôpital Maisonneuve-Rosemont or the CHUM, must prepare a detailed request demonstrating that standard therapies have failed or are not tolerated and that there is strong evidence the new drug will work for you.

This request is submitted to a provincial body called INESSS (Institut national d’excellence en santé et en services sociaux). INESSS evaluates the clinical evidence and cost-effectiveness, a process that can take one to two months. If approved, the medication is provided through your hospital pharmacy at no cost. If denied, there are appeal options, or you may need to seek coverage through private insurance if available. Navigating this administrative process can be stressful, which is why connecting with support services is so important. The Quebec Cancer Foundation, for example, offers invaluable guidance and financial assistance programs for patients facing these exact challenges, helping with everything from transportation costs to understanding the paperwork for accessing novel therapies.

How Lifestyle Changes Can Synergize with Treatment to Combat Tumor Progression?

While your medical treatment is managed by your expert oncology team, there is a growing body of evidence showing that you, the patient, can play a powerful and active role in your own care. Lifestyle factors—specifically diet, exercise, and stress management—are no longer seen as just “nice to have” additions but as synergistic elements that can significantly impact treatment tolerance and overall well-being. They can help your body better withstand the rigours of therapy and potentially improve outcomes.

Fatigue is one of the most pervasive side effects of any cancer treatment. The instinct is often to rest more, but counter-intuitively, gentle physical activity is one of the most effective remedies. In fact, numerous studies confirm that moderate exercise like 30-minute daily walks can reduce cancer-related fatigue by 25-30%. Similarly, nutrition plays a key role in managing side effects like diarrhea or taste changes and in reducing systemic inflammation. The goal isn’t to find a “magic” anti-cancer food, but to adopt a balanced, plant-forward diet that supports your body’s strength.

Here in Montreal, a wealth of resources exists to help you integrate these changes. You don’t have to figure it out alone. These programs are specifically designed for cancer patients and understand the unique challenges you face:

• Programme à Félix (Quebec Cancer Foundation): Offers free, supervised exercise and wellness programs tailored for cancer patients across the province.
• MUHC Nutrition Workshops: Provides practical, dietitian-led advice on managing dietary challenges during treatment.
• Cancer-Specific Yoga: Studios in areas like the Plateau Mont-Royal offer gentle yoga and meditation classes focused on stress reduction and mobility.
• Jean-Talon Market Tours: Some dietitians offer guided tours focusing on anti-inflammatory foods and fresh, local produce.
• Outdoor Activity: Gentle walking groups along the Lachine Canal or mindfulness sessions in Mount Royal Park during warmer months can provide both physical and mental benefits.

Your journey with immunotherapy is unique to you. By understanding the ‘why’ behind its effects, knowing the specific resources available to you in Montreal, and partnering actively with your care team, you can navigate this path with knowledge and confidence. The next step is to open this dialogue with your oncologist and infirmière pivot, armed with your questions and this newfound understanding.